METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs

1 . A method of treating, preventing, suppressing or inhibiting an urinary incontinence in a subject, comprising administering to said subject a SARM compound of Formula IA:

wherein

R 2 is H, F, Cl, Br, I, CH 3 , CF 3 , OH, CN, NO 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, alkyl, arylalkyl, OR, NH 2 , NHR, N(R) 2 , or SR;

R 3 is H, F, Cl, Br, I, CN, NO 2 , COR, COOH, CONHR, CF 3 , Sn(R) 3 , or R 3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, halogen, alkenyl or OH;

Z is NO 2 , CN, COR, COOH, or CONHR;

Y is CF 3 , F, Br, Cl, I, CN, or Sn(R) 3 ;

Q is CN, alkyl, halogen, N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;

or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:

n is an integer of 1-4; and

m is an integer of 1-3;

or its optical isomer, pharmaceutically acceptable salt, hydrate, or any combination thereof.

2 . The method of claim 1 , wherein said SARM compound is represented by a structure of Formula IIA:

wherein

Z is NO 2 , CN, COR, COOH or CONHR;

Y is I, CF 3 , Br, Cl, or Sn(R) 3 ;

Q is CN, alkyl, halogen, N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;

or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:

and R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, halogen, alkenyl or OH.

3 . The method of claim 1 , wherein said SARM compound is represented by the structure of Formula:

4 . The method of claim 2 , wherein said SARM compound is represented by a structure of Formula:

5 . The method of claim 1 , wherein said urinary incontinence comprises overactive/oversensitive bladder, overflow urinary incontinence, stress urinary incontinence, urge urinary incontinence or any combination thereof.

6 . The method of claim 1 , wherein said subject is a female.

7 . The method of claim 1 , wherein said subject is a postmenopausal woman.

8 . A method of reducing the occurrence or lessening the severity of at least one of the following symptoms in a subject suffering from urinary incontinence: (i) average daily frequency of urination; (ii) average nightly frequency of urination; (iii) total urinary incontinence episodes; (iv) stress incontinence episodes; and (v) urinary urgency episodes; comprising administering a SARM compound of Formula IA:

wherein

R 2 is H, F, Cl, Br, I, CH 3 , CF 3 , OH, CN, NO 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, alkyl, arylalkyl, OR, NH 2 , NHR, N(R) 2 , or SR;

R 3 is H, F, Cl, Br, I, CN, NO 2 , COR, COOH, CONHR, CF 3 , Sn(R) 3 , or R 3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, halogen, alkenyl or OH;

Z is NO 2 , CN, COR, COOH, or CONHR;

Y is CF 3 , F, Br, Cl, I, CN, or Sn(R) 3 ;

Q is CN, alkyl, halogen, N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;

or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:

n is an integer of 1-4; and

m is an integer of 1-3;

or its optical isomer, pharmaceutically acceptable salt, hydrate, or any combination thereof.

9 . The method of claim 8 , wherein said SARM compound is represented by a structure of Formula IIA:

wherein

Z is NO 2 , CN, COR, COOH or CONHR;

Y is I, CF 3 , Br, Cl, or Sn(R) 3 ;

Q is CN, alkyl, halogen, N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;

or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:

and R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, halogen, alkenyl or OH.

10 . The method of claim 8 , wherein said SARM compound is represented by the structure of Formula:

11 . The method of claim 9 , wherein said SARM compound is represented by a structure of Formula:

12 . The method of claim 8 , wherein said urinary incontinence comprises overactive/oversensitive bladder, overflow urinary incontinence, stress urinary incontinence, urge urinary incontinence or combination thereof.

13 . The method of claim 8 , wherein said subject is a female.

14 . The method of claim 8 , wherein said subject is a postmenopausal woman.

15 . A method of treating, preventing, suppressing or inhibiting pelvic floor disorders in a subject, comprising administering a SARM compound of Formula IA:

wherein

R 2 is H, F, Cl, Br, I, CH 3 , CF 3 , OH, CN, NO 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, alkyl, arylalkyl, OR, NH 2 , NHR, N(R) 2 , or SR;

R 3 is H, F, Cl, Br, I, CN, NO 2 , COR, COOH, CONHR, CF 3 , Sn(R) 3 , or R 3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, halogen, alkenyl or OH;

Z is NO 2 , CN, COR, COOH, or CONHR;

Y is CF 3 , F, Br, Cl, I, CN, or Sn(R) 3 ;

Q is CN, alkyl, halogen, N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;

or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:

n is an integer of 1-4; and

m is an integer of 1-3;

or its optical isomer, pharmaceutically acceptable salt, hydrate, or any combination thereof.

16 . The method of claim 15 , wherein said SARM compound is represented by a structure of Formula IIA:

wherein

Z is NO 2 , CN, COR, COOH or CONHR;

Y is I, CF 3 , Br, Cl, or Sn(R) 3 ;

Q is CN, alkyl, halogen, N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;

or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C

and R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, halogen, alkenyl or OH.

17 . The method of claim 15 , wherein said SARM compound is represented by the structure of Formula:

18 . The method of claim 16 , wherein said SARM compound is represented by a structure of Formula:

19 . The method of claim 15 , wherein said pelvic floor disorder comprises cystocele, vaginal prolapse, vaginal hernia, rectocele, enterocele, uterocele, and/or urethrocele.

20 . The method of claim 15 , wherein said subject is a female.

21 . The method of claim 15 , wherein said subject is a postmenopausal woman.

22 . A method of treating, preventing, suppressing or inhibiting an urinary incontinence in post-hysterectomy or post-oophorectomy women, comprising administering a SARM compound of Formula IA:

wherein

R 2 is H, F, Cl, Br, I, CH 3 , CF 3 , OH, CN, NO 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, alkyl, arylalkyl, OR, NH 2 , NHR, N(R) 2 , or SR;

R 3 is H, F, Cl, Br, I, CN, NO 2 , COR, COOH, CONHR, CF 3 , Sn(R) 3 , or R 3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, halogen, alkenyl or OH;

Z is NO 2 , CN, COR, COOH, or CONHR;

Y is CF 3 , F, Br, Cl, I, CN, or Sn(R) 3 ;

Q is CN, alkyl, halogen, N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;

or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:

n is an integer of 1-4; and

m is an integer of 1-3;

or its optical isomer, pharmaceutically acceptable salt, hydrate, or any combination thereof.

23 . The method of claim 22 , wherein said SARM compound is represented by a structure of Formula IIA:

wherein

Z is NO 2 , CN, COR, COOH or CONHR;

Y is I, CF 3 , Br, Cl, or Sn(R) 3 ;

Q is CN, alkyl, halogen, N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;

or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:

and R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, halogen, alkenyl or OH.

24 . The method of claim 22 , wherein said SARM compound is represented by the structure of Formula:

25 . The method of claim 23 , wherein said SARM compound is represented by a structure of Formula:

26 . The method according to claim 22 wherein said SARM compound provides androgen replacement.

27 . The method of claim 22 , wherein said urinary incontinence comprises overactive/oversensitive bladder, overflow urinary incontinence, stress urinary incontinence, urge urinary incontinence or combination thereof.

28 . A method of increasing the size and/or weight of muscles in the pelvic floor of a subject, comprising administering a SARM compound of Formula IA:

wherein

R 2 is H, F, Cl, Br, I, CH 3 , CF 3 , OH, CN, NO 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, alkyl, arylalkyl, OR, NH 2 , NHR, N(R) 2 , or SR;

R 3 is H, F, Cl, Br, I, CN, NO 2 , COR, COOH, CONHR, CF 3 , Sn(R) 3 , or R 3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, halogen, alkenyl or OH;

Z is NO 2 , CN, COR, COOH, or CONHR;

Y is CF 3 , F, Br, Cl, I, CN, or Sn(R) 3 ;

Q is CN, alkyl, halogen, N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;

or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:

n is an integer of 1-4; and

m is an integer of 1-3;

or its optical isomer, pharmaceutically acceptable salt, hydrate, or any combination thereof.

29 . The method of claim 28 , wherein said SARM compound is represented by a structure of Formula IIA:

wherein

Z is NO 2 , CN, COR, COOH or CONHR;

Y is I, CF 3 , Br, Cl, or Sn(R) 3 ;

Q is CN, alkyl, halogen, N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;

or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:

and R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, halogen, alkenyl or OH.

30 . The method of claim 28 , wherein said SARM compound is represented by the structure of Formula:

31 . The method of claim 29 , wherein said SARM compound is represented by a structure of Formula:

32 . The method according to claim 28 wherein said subject is a postmenopausal woman, a post-hysterectomy woman, a post-oophorectomy women or any combination thereof.

33 . The method of claim 28 , wherein said muscles comprise levator ani muscles, ischiococcygeus, coccygeus (COC) muscle, pubococcygeus (Pc) muscle, iliococcygeus (IL) muscle or any combination thereof.

34 . A method of increasing the size and/or weight of urethral sphincter of a subject, comprising administering a SARM compound of Formula IA:

wherein

R 2 is H, F, Cl, Br, I, CH 3 , CF 3 , OH, CN, NO 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, alkyl, arylalkyl, OR, NH 2 , NHR, N(R) 2 , or SR;

R 3 is H, F, Cl, Br, I, CN, NO 2 , COR, COOH, CONHR, CF 3 , Sn(R) 3 , or R 3 together with the benzene ring to which it is attached forms a fused ring system represented by the structure:

R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, halogen, alkenyl or OH;

Z is NO 2 , CN, COR, COOH, or CONHR;

Y is CF 3 , F, Br, Cl, I, CN, or Sn(R) 3 ;

Q is CN, alkyl, halogen, N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;

or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:

n is an integer of 1-4; and

m is an integer of 1-3;

or its optical isomer, pharmaceutically acceptable salt, hydrate, or any combination thereof.

35 . The method of claim 34 , wherein said SARM compound is represented by a structure of Formula IIA:

wherein

Z is NO 2 , CN, COR, COOH or CONHR;

Y is I, CF 3 , Br, Cl, or Sn(R) 3 ;

Q is CN, alkyl, halogen, N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;

or Q together with the benzene ring to which it is attached is a fused ring system represented by structure A, B or C:

and R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, halogen, alkenyl or OH.

36 . The method of claim 34 , wherein said SARM compound is represented by the structure of Formula:

37 . The method of claim 35 , wherein said SARM compound is represented by a structure of Formula:

38 . The method according to claim 34 wherein said subject is a postmenopausal woman, a post-hysterectomy woman, a post-oophorectomy women or any combination thereof.

39 . The method according to claim 1 , wherein said administering is of a composition comprising a 3 mg daily dose of said compound.

40 . The method according to claim 8 , wherein said administering is of a composition comprising a 3 mg daily dose of said compound.

41 . The method according to claim 15 , wherein said administering is of a composition comprising a 3 mg daily dose of said compound.

42 . The method according to claim 22 , wherein said administering is of a composition comprising a 3 mg daily dose of said compound.

43 . The method according to claim 28 , wherein said administering is of a composition comprising a 3 mg daily dose of said compound.

44 . The method according to claim 34 , wherein said administering is of a composition comprising a 3 mg daily dose of said compound.